Faeth Therapeutics, Inc. filed 4 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-17. Between them they name 4 people. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Karen Vousden, Director
On September 11, 2026, the Board of Directors (the "Board") of Faeth Therapeutics, Inc. (the "Company") increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately.
Appointed: Karen Vousden
Dr. Vousden has been elected as a Fellow of the Royal Society, the Royal Society of Edinburgh, the Academy of Medical Sciences, EMBO, the European Academy of Sciences, the American Association of Cancer Research and the American Academy of Arts and Sciences, and as a Foreign Associate of the U.S. National Academy of Sciences.
Appointed: Anand Parikh, President and Chief Executive Officer, effective 2026-06-13
Chief Executive Officer Appointment The Board of Directors (the "Board") of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company, effective as of June 13, 2026 (the "Effective Date").
Appointed: Brian Stephenson, Chief Financial Officer, effective 2026-06-13
Effective as of June 13, 2026, Brian Stephenson was appointed as the Company's Chief Financial Officer and principal financial officer.
Reported
The 2026 Plan has an initial share reserve equal to (i) 2,671,981 shares of the Company's common stock, par value $0.0001 per share (" common stock ") plus up to (ii) 311,164 shares of common stock subject to outstanding stock awards granted under the Company's 2021 Equity Incentive Plan that, after the date the 2026 Plan becomes effective, are not issued because a stock award expires or otherwise terminates without all of the shares covered by the award having been issued; are not issued because the stock award is settled in cash; are forfeited or repurchased because of the failure to vest; o
Appointed: Stephen M. Hahn, Director
Upon the effectiveness of their respective appointments, it is expected that: Dr. Hahn will serve as a Class III director and as a member of the Nominating and Corporate Governance Committee of the Board; Ms. Ramasastry will serve as a Class III director and as a member of the Audit Committee and of the Compensation Committee of the Board; and Ms. Vousden will serve as a Class II director and as a member of the Compensation Committee and as Chair of the Nominating and Corporate Governance Committee of the Board.
Find people with the same kind of experience as the Director at Faeth Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Faeth Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Faeth Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Faeth Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Faeth Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.